Yinchen Wuling San ameliorates high-fat diet-induced metabolic-associated fatty liver disease in rats by remodeling the gut microbiota
World Journal of Hepatology · 27.06.2026 · 18 (6)
DOI: 10.4254/wjh.118607 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.06.2026. Verfasst von Yi Zhang und 10 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Metabolic-associated fatty liver disease (MAFLD) is a common metabolic disorder characterized by hepatic steatosis, obesity, abnormal liver function, and dyslipidemia, with limited effective drug options available. Increasing evidence links MAFLD to dysbiosis of the gut microbiota and microbial metabolites, including short-chain fatty acids (SCFAs). We hypothesized that Yinchen Wuling San (YCWLS) mitigates MAFLD by remodeling gut microbiota and associated SCFAs profiles. AIM To determine whether YCWLS alleviates MAFLD by inducing gut microbiota remodeling in rats. METHODS A high-fat diet was used to induce MAFLD in rats. The animals were assigned to control, model, positive drug (Bifidobacterium quadruple live bacteria tablets, 2.1 g/kg), and YCWLS (6.38 g/kg) groups and treated for 4 weeks. Liver and adipose histopathology was evaluated using hematoxylin-eosin staining. Serum lipids and liver enzymes were measured, gut microbiota was profiled by 16S rRNA sequencing, and fecal SCFAs were quantified using gas chromatography-mass spectrometry. RESULTS Compared to the model group, YCWLS reduced the liver index and improved liver injury markers, specifically alanine aminotransferase and aspartate aminotransferase (alanine aminotransferase model 50.05 ± 8.98 vs YCWLS 22.97 ± 2.40 P < 0.01; aspartate aminotransferase model 217.32 ± 13.70 vs YCWLS 122.65 ± 6.49 P < 0.01), alleviating hepatic steatosis and tissue injury. YCWLS also decreased serum triglycerides, total cholesterol, and low-density lipoprotein cholesterol while increasing high-density lipoprotein cholesterol (triglycerides model 1.26 ± 0.18 vs YCWLS 0.61 ± 0.09 P < 0.01; total cholesterol model 2.83 ± 0.30 vs YCWLS 1.79 ± 0.09 P < 0.01; low-density lipoprotein cholesterol model 0.49 ± 0.16 vs YCWLS 0.17 ± 0.02 P < 0.01; high-density lipoprotein cholesterol model 0.50 ± 0.11 vs YCWLS 1.01 ± 0.09 P < 0.01). Microbiota analysis revealed a reduction in Firmicutes -related taxa (including Ruminococcaceae and Clostridiales ) and an increase in Verrucomicrobia , Lachnospiraceae , Peptostreptococcaceae , and Akkermansia . Most fecal SCFAs exhibited modest, non-significant increases; however, butyrate displayed a near-significant upward trend (P = 0.052). CONCLUSION Yinchen Wuling San improves liver injury and dyslipidemia in MAFLD rats and is associated with the enrichment of Akkermansia and Lachnospiraceae , supporting a gut microbiota-linked mechanism.
Zitieren
APA
Zhang, Y., Liu, J., Huang, A., Wang, Y., Cao, J., Li, M., Shi, D., Hu, Y., Deng, Q., Long, P., & Ai, B. (2026). Yinchen Wuling San ameliorates high-fat diet-induced metabolic-associated fatty liver disease in rats by remodeling the gut microbiota. World Journal of Hepatology, 18(6). https://doi.org/10.4254/wjh.118607
Vancouver
Zhang Y, Liu J, Huang A, Wang Y, Cao J, Li M, et al. Yinchen Wuling San ameliorates high-fat diet-induced metabolic-associated fatty liver disease in rats by remodeling the gut microbiota. World Journal of Hepatology. 2026;18(6). doi:10.4254/wjh.118607
BibTeX
@article{Zhang2026,
author = {Zhang, Yi and Liu, Jie and Huang, Ai-Si and Wang, Yu-Fei and Cao, Jie and Li, Mu-Lan and Shi, Dan-Dan and Hu, Yi-Lin and Deng, Qin and Long, Piao and Ai, Bi-Chen},
title = {Yinchen Wuling San ameliorates high-fat diet-induced metabolic-associated fatty liver disease in rats by remodeling the gut microbiota},
journal = {World Journal of Hepatology},
year = {2026},
volume = {18},
number = {6},
doi = {10.4254/wjh.118607}
}
EUVIMED